myeloid leukemia

(redirected from Myeloid leukaemia)
Also found in: Dictionary, Thesaurus, Medical.
Related to Myeloid leukaemia: Chronic myeloid leukaemia

myeloid leukemia

[′mī·ə‚lȯid lü′kē·mē·ə]
References in periodicals archive ?
Results of a first in-human, Phase 1/2 trial of ASP2215, a selective, potent oral inhibitor of FLT3/AXL, in patients with relapsed or refractory acute myeloid leukaemia.
David Ryner, Chair of the Chronic Myeloid Leukaemia Support Group, said: ""Although the number of patients qualifying for treatment will be limited, access to Iclusig represents an opportunity to make a significant difference to their lives.
TRAGIC LOSS Jordan Thompson died after a 19-month battle with acute myeloid leukaemia FAMILY AFFAIR Nina Hewitt and Andrea Thompson discovered they were related.
CML usually develops very slowly, which is why it is called 'chronic' myeloid leukaemia.
Fore Pharma's latest report 'Global Acute Myeloid Leukaemia Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Acute Myeloid Leukaemia market.
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
Professor Alan Burnett, of Cardiff University's School of Medicine, who led the study, said: "We already know that acute myeloid leukaemia is a collection of diseases.
Data from the largest clinical trial in newly diagnosed patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) demonstrate the longest overall survival observed to date in this disease area.
Dr Richard Clark,based at the Royal Liverpool Hospital,plans to study up to 40 patients with chronic myeloid leukaemia over the next three years.
Annwen, a nurse at Ysbyty Gwynedd, Bangor, was diagnosed in 1997 with a bone marrow disorder which developed into acute myeloid leukaemia.
A phase 1 dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
Bioenvision is also developing Evoltra(R) for the treatment of other haematological malignancies including for use as first line therapy of adult acute myeloid leukaemia (AML).